Gregg, Anthony R., Anita Schauer, Ou Shi, Zhouwen Liu, Caroline G. L. Lee, and William E. O'Brien. Limb reduction defects in endothelial nitric oxide synthasedeficient mice. Am. J. Physiol. 275 (Heart Circ. Physiol. 44): H2319-H2324, 1998.-Nitric oxide synthases are a family of enzymes capable of converting L-arginine to L-citrulline with the subsequent release of nitric oxide (NO) . NO has been shown to have multiple biologic effects depending on the isoform responsible for its production and its tissue of origin. Murine endothelial nitric oxide synthase (eNOS) is encoded by Nos3, located on mouse chromosome 5. NO produced from this isoform causes vascular smooth muscle relaxation. Other investigators have shown that the administration of nonspecific inhibitors of nitric oxide synthases to pregnant rats induces limb reduction defects. However, mice deficient in Nos3 have not previously been noted to show such abnormalities. To explore the importance of eNOS during development, we produced mice deficient in eNOS using embryonic stem cell technology. Limb reduction defects were seen in ϳ10% of the null animals. We also observed increased neonatal loss of homozygous deficient pups. One functional copy of Nos3 eliminates the risk of limb defects observed in our mouse strain. These findings have implications for understanding genetic predisposition to sporadic limb reduction defects in humans. nitric oxide; endothelium; homologous recombination NITRIC OXIDE (NO) is a molecule known to mediate physiological responses in the nervous system, immune system, and vascular smooth muscle. It is generated enzymatically by three distinct isoforms of nitric oxide synthase (NOS). The isoforms have been designated bNOS, which is located primarily in neurons; iNOS, found in macrophages and vascular smooth muscle; and eNOS, found in endothelial cells. These genes and the various physiological functions associated with them have been the subject of many studies and reviews (4, 11, 12, 21) .
One of the earliest recognized roles of NO in physiology was its function as an endothelium-derived relaxing factor (5). This production of NO is via the eNOS isoform, which is constitutive in the endothelial tissue. In response to receptor-and nonreceptor-mediated release, NO is capable of diffusing to surrounding vascular smooth muscle and, through a cGMP-mediated signal transduction pathway, vascular smooth muscle relaxation is accomplished. The capacity for endothelial cells to produce and release NO varies under a number of physiological and pathological influences (7, 14, 22) . Furthermore, production and release is known to vary among vascular beds (10) . More recently, NO derived from endothelium has been shown to mediate vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels (13) . The impact of this pathway on bone development has not been elucidated; however, NO produced by eNOS and iNOS in osteoblasts and osteoclasts has been shown to influence bone growth and remodeling (3, 18) .
Mice deficient in eNOS have increased blood pressure relative to controls (8, 16) . However, there are no reports of adverse reproductive function or developmental abnormalities in these mice. Using rat models fed nonspecific inhibitors of nitric oxide synthase during pregnancy, others (2, 15) have shown a 40-50% prevalence of limb defects.
MATERIALS AND METHODS

Generation of eNOS-deficient mice.
A 510-bp cDNA fragment was obtained by RT-PCR using mouse kidney RNA. The primer sequences were derived from published human and bovine Nos3 sequence data for exon 1 and exon 6. The respective 5Ј and 3Ј primer sequences are as follows: TGG-GAG(G/C)TGGGGAGCATC and GATCCGGAAGTCTCC(T/ G)CG. The cDNA generated was previously described (accession no. M93718) and was used to map the murine Nos3 locus (6) . The cDNA was used to screen a 129-SvEv genomic library. The targeting vector contained 3.6 kb of sequence 5Ј to exon 1, 2.2 kb of sequence 3Ј of exon 1, and a neomycin resistance gene selectable marker. The linearized targeting vector (25 µg) was electroporated into AB2.1 embryonic stem (ES) cells. Enrichment of targeted ES cells was performed in the presence of neomycin. DNA from clones was analyzed by Southern blot analysis, and cells from the G-12 clone that demonstrated the correct crossover event on each side of the selectable marker were injected into blastocysts to obtain chimeras. Chimeras were bred to C57Bl/6 females to obtain heterozygous (Nos3 m /ϩ) mice.
Animal husbandry. Approval for animal studies was obtained through the Internal Review Board at Baylor College of Medicine. Two breeding schemes were analyzed. One consisted of matings of Nos3 m /ϩ parents and the other of Nos3 m /Nos3 m parents. Matings were observed daily for the presence of new litters. Offspring were inspected for the presence or absence of limb defects through 21 days of life, at which time they were weaned and genotyped by Southern blot analysis. Matings were observed over a period of 4 mo. Statistical analysis employed for the comparison of outcomes was single-sample binomial proportions and Fishers exact test.
Immunohistochemistry. Slides containing Formalin-fixed cross sections of aorta were washed in 10 mM PBS (pH 7.4) with 0.05% Tween 20. Slides were incubated in antibody
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. diluent (0.1% sodium azide, 0.2% bovine serum albumin, 0.09% PBS, pH 7.4) containing the primary antibody [rabbit polyclonal anti-eNOS antibody (Affinity BioReagents, Golden, CO)]. After incubation for 1 h at 37°C, slides were washed in 10 mM PBS (pH 7.4) with 0.05% Tween 20 and incubated with secondary antibody [goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA)] for 20 min. Slides were then washed in 10 mM PBS (pH 7.4) with 0.05% Tween 20. After slides were washed, they were incubated for 20 min with an alkaline phosphatase-labeled horseradish-peroxidase complex in antibody diluent. Slides were color developed using nitro blue tetrazolium (DAKO, Carpenteria, CA). Color intensity was monitored by direct microscopic examination. Sections were counterstained with nuclear fast red for 10 min.
Vascular ring assays. To demonstrate an absent biologic response to acetylcholine-mediated relaxation among mice capable of producing eNOS (Nos3 m /ϩ) and those incapable of producing eNOS (Nos3 m /Nos3 m ), same-sex littermates were generated using an Nos3 m /Nos3 m ϫ Nos3 m /ϩ breeding pair. Mice were killed and dissected without knowledge of their genotypes. The entire descending thoracic aorta from the arch down to the diaphragm was carefully removed and cleaned of adherent fat and connective tissue. Care was taken to remove 3-mm vascular ring segments from the midportion of each thoracic aorta. Others (1, 7) have demonstrated variation in contractile and relaxation responses along the length of the aorta. The specimens were placed in iced, oxygenated Krebs buffer composed of (in mM) 119 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , 1.0 MgSO 4 , and 11.1 dextrose. Each ring was threaded onto two tungsten-wire (38-µm) triangles and suspended between a stationary rod and an isometric force transducer (Gould UC-2) in chambers containing warmed (37°C) Krebs buffer aerated with 95% O 2 -5% CO 2. After 1 h of equilibration, the optimal passive tension was determined for each ring by the contraction elicited by 80 mM KCl after incremental stretch. Cumulative addition (10 Ϫ8 -10 Ϫ6 M) of phenylephrine (Sigma), a vasoconstrictor, was followed by the cumulative addition (10 Ϫ6 and 10 Ϫ5 M) of acetylcholine (Sigma), an agent known to release endothelium-derived NO by muscarinic receptor activation.
Skeletal staining. The method used to stain bone and cartilage was as described (9) . Animals were eviscerated and placed in water overnight. Skeletons were immersed in a 65°C water bath for 1 min, skinned, and fixed in ethanol for 3 days. Alcian blue 8GX (15 mg, Sigma) was added to 80 ml of 95% ethanol and 20 ml of glacial acetic acid. Cartilage was stained for 8-12 h, rinsed in 100% ethanol overnight, and cleared in 2% KOH for 6 h. Alizarin red S (50 mg, Sigma) was added to 1 liter of 2% KOH, and skeletons were immersed for 3 h to counterstain bone. Skeletons were cleared in 2% KOH and stored in 100% glycerol.
RESULTS
Construction of eNOS-deficient mice.
We designed a targeting vector for the Nos3 locus that deletes part of the promoter region and exon 1 of the gene. The section of DNA that was removed was sequenced in its entirety and submitted to GenBank (accession no. AF045940). Analysis of this DNA did not reveal the presence of any potential exons other than those of the eNOS gene. The removal of exon 1 results in the elimination of the first 54 amino acids of the protein and leaves the remainder of the sequence out of frame. The next closest methionine is in exon 5.
Nos3-deficient mice (Nos3 m /Nos3 m ) were generated using ES cell technology (Fig. 1A) . The targeting vector was electroporated into the AB2.1 line of ES cells. Of 400 ES cells screened by Southern blot analysis, 16 were correctly targeted. The recombinant allele was detected by restriction endonuclease digestion of ES cell DNA with EcoR I, followed by Southern blot analysis using either the 5Ј or 3Ј probes shown in Fig.  1A . A 4.8-kb fragment for the deletion versus a 9.8-kb fragment for the wild-type locus is diagnostic of the recombination event from the 5Ј arm. A 6.5-kb fragment versus a 9.8-kb fragment is diagnostic of the recombination event from the 3Ј arm. Southern blotting of DNA from deficient mice showed the expected alteration in gene structure (Fig. 1B) . Germ-line transmission of the DNA alteration from chimeric males was achieved. Loss of eNOS expression was confirmed by immunohistochemistry (Fig. 2) . Note the intense staining of the endothelium denoted by arrows in the section from normal animal ( Fig. 2A) versus the complete absence of staining in the Nos3 m /Nos3 m animal (Fig.  2B) . The staining of the red blood cells and fat tissue noted in the normal animal is an artifact of the staining protocol.
A previous study (8) using vascular rings from eNOSdeficient mice demonstrated the absence of vascular smooth relaxation after exposure of preconstricted vascular rings to acetylcholine. Aortic segments from our Nos3 m /Nos3 m mice failed to relax in response to administration of acetylcholine. Aortic ring segments from Nos3 m /ϩ animals resulted in a dose-dependent relaxation after muscarinic receptor activation (Fig. 3A) . However, ring segments from the Nos3 m /Nos3 m animals failed to relax under identical conditions (Fig. 3B) . Consistent with an increased vasoconstrictor response to phenylephrine in the absence of constitutively released NO, the scale sensitivity was reduced from 200 to 500 mV (asterisk in Fig. 3B ). The need to continue recording at 500 mV was confirmed after the addition of 10 Ϫ6 M acetylcholine. One striking observation noted when breeding Nos3 m / Nos3 m animals was the presence of limb-reduction defects in their offspring. These defects were observed in Nos3 m /Nos3 m offspring only (Table 2) . Of 185 Nos3 m / Nos3 m animals analyzed, 16 (ϳ8%) had significant limb abnormalities. The rate was similar for homozygous deficient pups derived from heterozygous matings (10%, Table 2 ). Of 175 Nos3 m /ϩ animals studied, no abnormalities were noted, and there were no defects noted among 85 ϩ/ϩ mice. A spectrum of the abnormalities observed is shown in Fig. 4 . The abnormalities observed in Nos3 m /Nos3 m mice ranged from meromelia to syndac-H2320 LIMB ABNORMALITIES IN ENOS-DEFICIENT MICE tyly (not shown). All limb deficiencies were terminal and transverse and involved the hindlimbs and forelimbs to an equal extent. In affected animals, skeletal staining revealed hypoplasia of the carpals, metacarpals, radius, and ulna (Fig. 4, B and C) . Gender was not a predisposing factor for the development of limb defects. In addition, there was no predilection for sidedness. There was no correlation between the identification of limb defects and survival among Nos3 m / Nos3 m mice.
Analysis of phenotypes of
DISCUSSION
Successful limb development is known to involve inductive interactions between the lateral plate mesoderm and apical ectodermal ridge (17) . This process, 
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together with uninterrupted osseous development, requires a functioning capillary network that provides osteoblast progenitors as well as sufficient oxygen and nutrition to cells undergoing growth and differentiation. Given the 120 bones that make up the upper and lower extremities in humans, an estimated 1.3 ϫ 10 36 single or multiple limb deficiencies are possible. One estimate is that major limb malformations in humans are observed in 3-8 of 10,000 live-born infants (17) . Several mechanisms for limb deficiency in humans have been put forth (17) . The type of deficiency seen in Nos3 m /Nos3 m mice is not consistent with that observed as a result of a neuropathic process (sclerotomal distribution). This mechanism more frequently effects the lower extremities and is intercalary in nature. Aberrant induction of mesoderm by the apical ectodermal ridge, another possible mechanism, can lead to a heterogeneous group of limb deficiencies including intercalary defects. None of these were observed in our mutant mice.
Vascular insults are known to give rise to limb reduction abnormalities (19) . The nature of vascular insults may be a reduction in blood flow secondary to prolonged or intense vasoconstriction, thromboembolic events, or impaired angiogenesis. Perturbations of the fetal vasculature likely underlie many of the limb disruptions observed in clinical medicine. It was recently emphasized that a fairly common condition, ''amniotic band disruption sequence,'' results from a resorbing dead twin showering emboli to a live twin at an early developmental stage (20) . This condition is associated with terminal, transverse limb abnormalities. These authors speculate that amniotic bands may be a consequence of the vascular disruption and not a cause of the vascular disruption. Thalidomide, an angiogenesis inhibitor, has a history of associated limb reduction abnormalities in exposed fetuses (17) . Supporting a role for NO in angiogenesis, VEGF was been shown to mediate angiogenesis in the microvasculature through a mechanism dependent on NO (13) .
Given the well-known role of NO in mediating vascular smooth muscle relaxation, its ability to promote blood clotting through the activation of platelets, and its role in angiogenesis, it is no surprise that developmental defects have been observed in our deficient mice. The morphology of the limb defects we report are consistent with a vascular mechanism, i.e., they are terminal and transverse. Upper limbs were more commonly affected, and defects tended to be unilateral. Furthermore, syndactyly has also been attributed to the mechanism of distal hemorrhage. The recognized dependence of bone and cartilage on vascular invasion supports a role for NO in limb and digit development. In summary, the pattern of limb defects observed in Nos3 m /Nos3 m mice most closely resembles that which is observed in humans and is believed to be due to vascular deficiency.
Targeting constructs reported by others who have generated eNOS-deficient mice have created deletions in the NADPH (8) and calmodulin (16) binding sites. Our construct deleted the first exon and part of the promoter region. Other reports included biologic evidence for altered vascular responsiveness as well as molecular evidence to confirm deficient eNOS production. We have provided similar evidence and therefore do not believe that a variation in targeting strategy accounts for our report of limb-reduction defects. Re- duced penetrance of the eNOS mutation could explain why others have not observed limb-reduction defects. In addition, our laboratory is specifically interested in the impact of NO on reproductive processes. Reports suggest that others are focused on the antihypertensive role of NO rather than the impact of NO on development. Our founder mouse (Fig. 4D) was not identified until adulthood. Furthermore, surveillance of offspring before this time consisted almost exclusively of weighing and counting offspring. Once our founder mouse was identified, surveillance of offspring changed from a semi-weekly approach to a daily approach with careful examination of the limbs. This change in surveillance accounts for our ability to report an 8-10% incidence of limb abnormalities in eNOS-deficient mice.
The data presented herein demonstrate a significant role for eNOS in normal and abnormal limb development. We propose that the basis for the abnormalities is insufficient capillary blood flow to the developing limb as well as the possibility of occlusion and hemorrhage, resulting in terminal, transverse limb disruptions. The heterogeneity of limb deficiencies lends further support for the concept that vascular insufficiency over a range of developmental stages yields the abnormalities seen in the Nos3 m /Nos3 m mice. Our observations show that eNOS deficiency is necessary, but not sufficient, to cause limb deficiency in the mouse embryo. The reasons for the reduced penetrance of these limb deficiencies remains to be explained. Possibilities include modifier genes, the relationship of placental implantation to uterine blood flow, redistribution of fetal circulation in response to fetal and/or maternal physiological changes, and stochastic events.
